News
Bridgewater firm's stock jumps after FDA approves its new lung disease drug
BRIDGEWATER – Shares of Insmed, a pharmaceutical firm at the intersection of Route 202-206 and Allen Road, jumped 8% on the NASDAQ after the federal Food and Drug Administration approved the company's new drug to treat a lung disease.
Stocktwits on MSN2d
HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week
H.C. Wainwright on Wednesday doubled its price target on Insmed (INSM) to $240 from $120 while keeping a ‘Buy’ rating on the ...
Insmed has claimed the distinction of becoming the first company to get FDA approval for a treatment for chronic lung disease ...
Insmed's Brinsupri is the first DPP1 inhibitor approved by the FDA and the first treatment for bronchiectasis to reach the ...
The FDA granted approval to brensocatib for treating adults and children aged at least 12 years with non-cystic fibrosis ...
PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced ...
With a landmark U.S. approval Tuesday, Insmed is making waves with a new class of drug that’s also the first to be green lit in the chronic lung disease bronchiectasis. | The FDA on Tuesday signed ...
Insmed has won U.S. Food and Drug Administration approval of Brinsupri as the first and only treatment for the chronic lung disease non-cystic fibrosis bronchiectasis. Insmed on Tuesday said the FDA ...
Maxor Specialty Pharmacy, a VytlOne company, was selected by Insmed to be a limited distribution provider of Brinsupri™. Brinsupri is a dipeptidyl peptidase 1 (DPP1) inhibitor indicated for the ...
Q2 2025 Earnings Call Transcript August 7, 2025 Insmed Incorporated misses on earnings expectations. Reported EPS is $-1.7 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback